A sound investment process and strong management team underpin Invesco Dorsey Wright Healthcare MomtETF's Morningstar Medalist Rating of Silver. The portfolio maintains a cost advantage over competitors, priced within the cheapest fee quintile among peers.  

 The strategy's effective investment philosophy supports an Above Average Process Pillar rating. Independent of the rating, analysis of the strategy's portfolio shows it has maintained a significant overweight position in momentum exposure and volatility exposure compared with category peers. Momentum exposure is attributed to holding stocks currently on a winning streak and selling those that are on a downtrend. And high volatility exposure is rooted in stocks that have a higher standard deviation of returns. The strategy’s management team earns an Above Average People Pillar rating. The strategy's parent organization earns the firm an Average Parent Pillar rating. People Pillar and Parent Pillar ratings for this strategy are indirectly assigned by a Morningstar analyst rather than algorithmically derived. Please see the notes following each pillar section for more details. The details of assigning methods can be found in each pillar section.

Analyst Rating

Eli Lilly

IDEXX Laboratories

Medpace Holdings

Alpine Immune Sciences

Tenet Healthcare

ImmunityBio

Natera

CoreSite Realty

Vera Therapeutics

Regeneron Pharmaceuticals

Morningstar's evaluation of this security's process aims to determine the likelihood that it will outperform its Morningstar Category benchmark on a risk-adjusted basis over the long term. Invesco Dorsey Wright Healthcare MomtETF earns an Above Average Process Pillar rating. 

The most meaningful contributor to the rating is that this fund tracks an index. Historical data, such as Morningstar's Active/Passive Barometer, finds that passively managed funds have generally outperformed their active counterparts, especially over longer time horizons. Impressive risk-adjusted performance also influences the rating. This can be seen in the fund's five-year alpha calculated relative to the category average, which suggests that the managers have shown skill in their allocation of risk. Lastly, the process is limited by the parent firm's five-year risk-adjusted success ratio of 44%. The measure indicates the percentage of a firm's funds that survived and beat their respective category's median Morningstar Risk-Adjusted Return for the period. The parent's relatively low success ratio suggests that the firm could do better across its fund lineup.

 This strategy tends to hold smaller, more growth-oriented companies than its average peer in the Health Morningstar Category. Examining additional factor exposure, this strategy has consistently had exposure to high-momentum stocks compared with Morningstar Category peers over the past few years. Momentum approaches bet that rising stocks will continue to rise and that lagging stocks will continue to lag. In recent months, the strategy was more exposed to the Momentum factor compared with its Morningstar Category peers as well. This strategy also has had an overweight bias to the volatility factor over these years, meaning it has owned companies that have a higher historical standard deviation of returns. Such exposure tends to pay off when markets are hot and to be costly when they are not. Compared with category peers, the strategy also had more exposure to the Volatility factor in the most recent month. In addition, this strategy has exhibited a tilt toward liquid assets, evidenced by consistently holding companies with relatively higher trading volumes. Such stocks may have less potential upside than illiquid holdings, but they are easier to trade during market downturns. In this month, the strategy also had more exposure to the Liquidity factor over its peers. More information on a fund and its respective category's factor exposure can be found in the Factor Profile module within the Portfolio section. 

 The portfolio has allocations in its top two sectors, financial services and energy, that are similar to the category. The sectors with low exposure compared to category peers are healthcare and basic materials; however, the allocations are similar to the category. The portfolio is positioned across 60 holdings and is diversified among those holdings. In its most recent portfolio, 35.9% of the strategy's assets were concentrated in the top 10 fund holdings, as opposed to the category’s 41.0% average. And in closing, in terms of portfolio turnover, on a year-over-year basis, 219% of the fund's holdings have changed, whether through increasing, decreasing, or changing a position.

Above Average

Process

Invesco’s equity team is strong compared with others in the industry, resulting in an Above Average People Pillar rating. There are four managers listed on the fund: Peter Hubbard, Tony Seisser, Michael Jeanette, Pratik Doshi. The team is well equipped, with an average of 12 years of portfolio management experience. Together, they manage a total of 145 strategies, with a Bronze asset-weighted average Morningstar Medalist Rating, demonstrating their potential to deliver positive alpha relative to the category median in aggregate. This group has successfully retained management talent, with no departures in the past five years. 

 Note: This People Pillar rating is indirectly assigned by an analyst. Morningstar analysts evaluate the People Pillar for passive products at the brand level and may also differentiate by asset class. There is at least one other passive strategy at the firm that is covered by a Morningstar analyst, so the People Pillar rating of the fund is inherited from the rating that the Morningstar analyst assigned to investment vehicles under the same brand name.

People

Invesco succeeds in a number of areas but also has its share of subpar offerings, along with many others that land somewhere in the middle. A mid-2023 change of CEO, from longtime chief Marty Flanagan to veteran Invesco executive Andrew Schlossberg, is noteworthy, and several other executives retired or departed in 2023. Portfolio-manager shuffles aimed at bolstering poor performers, which began under Flanagan, have continued under Schlossberg, who told Morningstar his most important aim is bolstering “investment quality.” However, major changes of direction or approach are unlikely. The firm retains a Morningstar Parent rating of Average. 
Invesco’s international-equity teams in Texas and New York remain solid. However, the extensive U.S.-equity lineup needs improvement. Fixed-income offerings run the gamut: The multisector and short-term-bond areas are good, but corporate high-yield is less impressive. The firm’s exchange-traded fund lineup includes the popular Nasdaq-focused QQQ; passive strategies make up around 37% of Invesco’s assets under management. Invesco has not been averse to trying new types of strategies, and it was among the firms that immediately launched a spot bitcoin ETF after SEC approval in early 2024.
The picture outside the United States is mixed. Fund performance has been subpar in Asia, and while the picture has brightened in the United Kingdom and Europe, that region still can’t be considered a strength.

Average

Parent

Invesco DWA Healthcare Momentum ETF

PTH tracks an index of U.S. healthcare firms selected and weighted by price momentum.

Loncar Cancer Immunotherapy ETF

Specialized health-care exchange-traded funds outperformed the broader stock market Wednesday even as stocks rebounded from a sell-off that left the Nasdaq Composite Index  in correction territory. The Invesco DWA Health Care Momentum ETF  jumped 4.6%, making it among the biggest fund gainers at midday, and putting it on track for its best day since June 15, according to FactSet data.

Specialty biotech funds jump on promising coronavirus, funding news

FFCM Shs AGFiQ US Market Neutral Value Fund

First Trust NASDAQ Clean Edge Green Energy Index Fund

Invesco Solar ETF

iShares 20+ Year Treasury Bond ETF

ProShares VIX Short-Term Futures ETF

iPath S&P 500 VIX Short-Term Futures ETN Class A

PIMCO 25+ Year Zero Coupon US Treasury Index ETF

After a massive rally, Wall Street suffered its worst day in almost three months as investors' dumped the high-flying technology stocks.

ETF Winners & Losers From Wall Street's Worst Day Since June

ARK Genomic Revolution Multi-Sector ETF

KraneShares MSCI All China Health Care Index ETF

The best healthcare ETFs for Q4 2020 are ARKG, KURE, and PTH.

Best Healthcare ETFs for Q4 2020

Amplify AI Powered Equity ETF

iShares U.S. Healthcare Providers ETF

The ongoing boom in online care and consultations has led to merger & acquisition activity in the telehealth services space.

ETFs Set to Surge on Virtual Healthcare Deal

Schwab US Dividend Equity ETF

VanEck Vectors Semiconductor ETF

YieldShares High Income ETF

iShares Silver Trust

A consensus carried out from 1950 to 2019 shows that August posted an average equity return of negative 0.26%.

6 ETF Picks for Historically Downbeat August

AstraZeneca

First Trust Nasdaq Pharmaceuticals ETF 

Amplify Treatments Testing & Advancements ETF

Renaissance IPO ETF

Moderna

Novavax

Pfizer

VanEck Vectors Pharmaceutical ETF

Vaxart

There are at least a hundred candidates in the COVID-19 vaccine race globally. However, few companies like Moderna, Pfizer and AstraZeneca are showing considerable hope.

COVID-19 Vaccine Push Brings Hope: Stock & ETF Beneficiaries

ProShares Long Online/Short Stores ETF

VanEck Video Gaming and eSports ETF

iShares Genomics Immunology and Healthcare ETF

Invesco QQQ

SPDR S&P 500 ETF Trust

S&P Forecasts And Strongly Outperforming Funds

iShares Nasdaq Biotechnology ETF

SPDR S&P Biotech ETF

Biotechnology sector-related exchange traded funds were among the best performers Tuesday as the government program “Operation Warp Speed” allocates billions of dollars for a quick development and delivery of a coronavirus vaccine. On Tuesday, the Invesco DWA Healthcare Momentum Portfolio (NASDAQ: PTH) rose 3.6%, SPDR S&P Biotech ETF (XBI) gained 2.5% and iShares Nasdaq Biotechnology [.

Biotech ETFs Rally as ‘Operation Warp Speed’ Fuels Covid-19 Research

Fidelity MSCI Health Care ETF

iShares U.S. Medical Devices ETF

Invesco S&P 500 Equal Weight Health Care ETF

SPDR S&P Health Care Equipment ETF

Between the novel coronavirus and an election year, these healthcare ETFs appear poised to post strong growth into 2021.

7 Healthcare ETFs Which Should Continue Growing Into 2021

Breakwave Dry Bulk Shipping ETF

Microsoft

United States Gasoline Fund LP

Last week was moderate for the Wall Street despite rising coronavirus cases.

Markets Brave Coronavirus Second Wave: 5 Best ETFs of Last Week

Invesco Dynamic Media ETF

Invesco S&P SmallCap Health Care ETF

ProShares Short Financials

Pacer Funds Trust-Pacer Benchmark Data & Infrastructure Real Estate Sector ETF

Communication Services Select Sector SPDR Fund

COVID-19 has brought lasting impacts to many industries & changed consumers' habits.

Portfolio Management During Uncertainty: COVID-19

Emerging Markets Internet & Ecommerce ETF

Renaissance International IPO ETF

Proshares Online Retail ETF

Invesco NASDAQ Internet ETF

Relative momentum filtering can sometimes identify overlooked niche securities lost in the enthusiasm for the giant winners.

Filtering For ETFs That Outperformed Blended FANMAG Stocks

Several companies sit at the forefront of developing a coronavirus vaccine. Gain exposure to each using the following three ETFs.

3 ETFs in Focus as Race for Vaccine Intensifies

Global X Gold Explorers ETF

Amplify Junior Silver Miners ETF

Barclays Inverse US Treasury Composite ETN

Though last week was not upbeat for Wall Street, these ETFs breezed past Wall Street.

Wining ETF Areas of Last Week

The fund PTH hit a 52-week high on May 11. Can it sustain the rally?

Healthcare ETF (PTH) Hits New 52-Week High

The best Healthcare ETFs for Q3 2020 are ARKG, KURE, and PTH.

Best-Performing Healthcare ETFs for Q3 2020

First Trust Dorsey Wright Momentum & Low Volatility ETF

iShares MSCI USA Momentum Factor ETF

Invesco DWA Technology Momentum ETF

These high-momentum ETFs and stocks could be good ways to play the latest optimism in the market.

High Momentum ETFs & Stocks to Bet on

VanEck Vectors Biotech ETF

First Trust NYSE Arca Biotechnology Index Fund

iShares U.S. Pharmaceuticals ETF

Invesco Dynamic Biotechnology & Genome ETF

ALPS Medical Breakthroughs ETF

SPDR S&P Health Care Services ETF

SPDR S&P Pharmaceuticals ETF

Biotech and healthcare ETFs were pretty stable on Apr 23 despite the news that Gilead's Remdesivir failed to improve Covid-19 patients' condition.

Healthcare & Biotech ETFs Digest GILD's Failure News: 5 Winners

NuShares ESG Mid-Cap Growth ETF

Invesco S&P 500 Quality ETF

Vanguard High Dividend Yield ETF

Technology Select Sector SPDR Fund

U.S. economy is probably witnessing a mini-reflation wave within an ongoing late cycle, per some analysts. One can play the trend with these ETFs.

US Economy in "Late-Cycle" Phase? ETFs to Play

Decent fundamentals and valuations as well as encouraging developments put these medical ETFs and stocks in focus.

Healthcare Drives Wall Street: 5 Soaring ETFs

Sprott Gold Miners ETF

Materials Select Sector SPDR Fund

We have presented a bunch of top-performing ETFs so far this month that will continue to outperform if the current trends continue.

Best June for Stocks in Decades: 5 Best ETFs

Wall Street on Pace for Best June in Decades: 5 Best ETFs

Xtrackers Harvest CSI 500 China A-Shares Small Cap ETF

AdvisorShares Dorsey Wright Short ETF

VelocityShares VIX Short-Term ETN

SPDR S&P Semiconductor ETF

In the light of recent positive developments, here we highlight the best and the worst-performing ETFs to start June.

ETF Winners & Losers of Last Week

Vanguard S&P Mid-Cap 400 Growth ETF

PTH and IVOG saw massive trading volumes in yesterday trading session.

Healthcare and Mid-Cap: 2 ETFs to Watch on Outsized Volume

News for Invesco DWA Healthcare Momentum ETF ETF (PTH)